ERBB2 and pancreatic neoplasm: Our results demonstrate that HER3 is essential for pertuzumab efficacy in HER2low-expressing pancreatic tumor xenografts and suggest that the combination of this antibody with an anti-HER3 antibody could be a new potential treatment for pancreatic cancers that co-express HER2 and HER3.